Annual report pursuant to Section 13 and 15(d)

Schedule of Identifiable Assets Carrying Value (Details)

v3.23.1
Schedule of Identifiable Assets Carrying Value (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Total $ 31,951 $ 31,951
Accumulated Amortization (31,090) (29,819)
Net Carrying Value $ 861 2,132
CLIA Lab [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful life 2 years 3 months 18 days  
Total $ 609 609
Asuragen Acquisition [Member] | Thyroid [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful life 9 years  
Total $ 8,519 8,519
RedPath Acquisition [Member] | Pancreas Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful life 7 years  
Total $ 16,141 16,141
RedPath Acquisition [Member] | Barrett's Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful life 9 years  
Total $ 6,682 $ 6,682